anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
The invention discloses a kind of calcium carbonate D to replenish the calcium for children 3 Chewable tablets and preparation method thereof, the chewable tablets are made of following component: calcium carbonate, vitamin D 3 Powder, maltodextrin, mannitol, magnesium stearate, essence.Preparation step is as follows: it is qualified that supplementary material needed for 1. is examined, spare after progress pre-treatment respectively；2. suspension is made in calcium carbonate, aqueous solution is made in maltodextrin, and the two is uniformly mixed；3. spray drying prepares the maltodextrin embedding composition granule of calcium carbonate；4. whole grain；5. total mix；6. measuring intermediates content, tabletting, bottling.The present invention uses spray drying technology, and the sand type of calcium carbonate can be effectively improved with maltodextrin embedding；Direct tablet compressing technology enormously simplifies production technology, and hardness is suitable for taking convenient for children&#39;s chewing.
Therapeutic substances such as salicylate drugs, cincophen, amidopyrine and the sulphonamides, which ordinarily have a toxic or depressant effect on tissue metabolism or tissue respiration when adminisstered in frequent and extended dosages, are rendered non-toxic at such dosages by admixture with at least one non-toxic aliphatic, polycarboxylic acid substance of general formula R1(COOR)x where x=2 or 3; R=hydrogen, ammonium, alkali metal or alkaline earth metal; and R1 is succinic, fumaric, malic, oxalacetic, cisaconitic, isocitric or  -ketoglutaric acids stripped of their carboxyl groups. The dibasic acids and in particular succinic acid, are preferred. Succinic acid and its ammonium, sodium or calcium salts are particularly effective.  In one example, tablets are prepared from 3 parts of calcium succinate and 4 parts of acetylsalicylic acid. Effective compositions have 1/3 to 10 parts of calcium succinate to 1 part of acetylsalicylic acid, although a ratio of 1:1 to 3:1 is preferred.  By a salicylate drug is intended salicylic acid, its esters such as ethyl salicylate, its acyl derivatives such as acetylsalicylic acid and methylene citryl salicylic acid and the ammonium, alkali and alkaline earth metal salts of such acids. Sulphathiazole and &#34;Atebria&#34; (R.T.M.) are other specified therapeutic substances.
The invention discloses the function of CH25H (cholesterol-25-hydroxylase) and 25-OHC in immune response and application thereof as an immunomodulator in vaccines. The invention finds that 25-OHC can significantly inhibit inflammation immunologic reaction, can inhibit immune cell overexpressed IL-1b and TNF-a, and has very important application value for adjustment of virus infection patient persistent immune activation and inflammatory reaction. Without affecting antigen specific T lymphocyte proliferation, 25-OHC strongly inhibits mitogen stimulated lymphocyte overproliferation effect. 25-OHC can be used as the immunomodulator of a HIV (human immunodeficiency virus) vaccine to improve the immune effect of the vaccine, and can be widely applied to prevention and treatment of AIDS. The mentioned immunomodulatory effect is in favor of designing a new generation of HIV vaccine, i.e. reducing CD4&lt;+&gt; T cell immune response to the greatest extent without affecting body protective CD8&lt;+&gt; T cell immune functions.
PROBLEM TO BE SOLVED: To increase the solution velocity of alkali metal hydrogencarbonate granules to water by specifying the concn. of an aq. binder soln. when base particles contg. at least one kind of alkali metal hydrogencarbonate and having a specified average particle diameter are mixed with the binder soln. and the granules are produced. SOLUTION: Base particles contg. at least one kind of alkali metal hydrogencarbonate and having $150μm average particle diameter are mixed with an aq. soln. of a binder reducing the solubility of the base and alkali metal hydrogencarbonate granules fit for medicines, etc., are produced. At this time, the concn. of the binder soln. is regulated to &gt;=35wt.% of the saturation concn. of the binder to water and the binder is used by 0.1-14wt.% of the amt. of the base. An alkali metal salt is preferably used as the binder. When the base is sodium hydrogencarbonate, an inorg. or org. acid salt of an alkali metal is preferably used. The diameter of produced granules is not especially limited but is preferably 0.5-10mm.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a technique of moistening the skin by bringing the fabric having germanium deposited by sputtering into contact with the skin or by positioning it near the skin.  &lt;P&gt;SOLUTION: The fabric has the germanium or a germanium alloy deposited thereon by sputtering. For the germanium alloy, Ge-In, Ge-Sn, Ge-Ti, Ge-Fe, Ge-Si, Ge-Si-Ti, Ge-In-Ti, etc. are mentioned. The germanium content of the alloy is preferably 50 mass% or more. As for sputtering, so-called low-temperature sputtering is preferable. The low-temperature sputtering is executed by keeping a distance of about 5 cm or more from the target fabric so that the temperature of the fabric may not rise so much. The sputtering temperature is normally 50-250°C, preferably 100-180°C, and the vacuum is normally 1×10-2 to 1×10-6, preferably 1×10-3 to 1×10-5. The thickness of a sputtering film thus formed is normally 50-300 nm, preferably 80-150 nm. Sputtering may be applied to either one side of the fabric alone or both sides thereof. In the case of woven fabric, the sputtering may be conducted after fabric is woven, while fibers subjected to the sputtering may be woven into the fabric as well.  &lt;P&gt;COPYRIGHT: (C)2004,JPO
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a method for producing cyclododecatriene by trimerizing butadiene in the presence of a catalytic system and a solvent by a continuous or discontinuous method.  &lt;P&gt;SOLUTION: The method for producing the cyclododecatriene is carried out as follows. A compound containing at least one kind of elements of main group 5 in the elemental periodic table is added to the catalytic system, and the solvent is allowed to contain 10-1,000 ppm polar component of general formula HO-R before addition of the catalytic components. The reaction temperature is ≤140°C when a nickel-containing catalytic system is used, and ≤80°C when a titanium-containing catalytic system is used. The obtained crude cyclododecatriene can be isolated by distillation, and cyclooctadiene formed as a by-product can also be isolated from the crude product.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To make a substance containing β-cryptoxanthin component be sufficiently dissolved in foods and drinks or soaps/cosmetics and uniformly dispersed.  &lt;P&gt;SOLUTION: The extract liquid containing the β-cryptoxanthin component to be incorporated into foods and drinks is obtained by dissolving or dispersing the extract containing the β-cryptoxanthin component in a solvent containing fats and oils or an emulsifier. The extract liquid containing the β-cryptoxanthin component to be incorporated into a soap or a cosmetic is obtained by dissolving or dispersing the extract containing the β-cryptoxanthin component in a solvent containing fats and oils or an emulsifier. The foods and drinks or the soap or the cosmetic are obtained by incorporating these extract liquids containing the β-cryptoxanthin component. Preferably, these extracts containing the β-cryptoxanthin component are ones extracted from a persimmon fruit.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
FIELD: inhalers. SUBSTANCE: inhaler of dry powder-like medicament has impeller positioned eccentrically in mixing chamber. Impeller is rotated by motor at high speed. Plunger feeds dose of medicinal powder into chamber so that all particles of powder are available for mixing, decomposing and grinding. Hole receives first flow of air and directs it to mouthpiece for user&#39;s inhalation. At least one hole is provided in wall designed to deflect part of main air flow to spraying chamber for mixing with particles and forming thin low- density dry aerosol of powder-like medicament for user&#39;s inhalation. Device ensures medicament feed irrespective of patient&#39;s breathing intensity. EFFECT: enhanced efficiency. 11 cl, 37 dwg
The capsules have, inside the standard hard gelatin capsule, &gt;=1 additional hard gelatin capsule with same or different dissolution characteristics. Inside the inner capsule is the same or different pharmaceutical carrier in same or different formulation, or a mixt. of various formulations. The hard gelatin may be replaced by other suitable capsule material, e.g., the inner capsule is of soft gelatin. Used for administration of medicines with physicochemical and/or pharmacokinetic incompatibilities such as vitamins and enzymes. The incompatible components can be kept apart during storage without need for special formulations and additional additives. By controlling capsule solubility, the time and position of release of ingredients can be regulated.
The invention relates to medicine, more specifically hepatology, and can be used for treating chronic viral hepatitis C, the causative agent of which can be of any genotype. The technical result of the proposed method is a reduction in the aggressiveness of antiviral therapy together with an increase in stable positive therapeutic results. In the claimed method for treating chronic viral hepatitis C, which involves administering short-lived interferon-alpha (IFN) and the nucleoside analogue Ribamidil to the patient, an average weekly starting dose of interferons in a range of 10.5-21.0 million SU is determined on the basis of the patient&#39;s own interferon-alpha level, and interferon-alpha is administered with an at least twofold gradual increase in the average weekly dose of interferons to a value of 21.0-84 million SU. Throughout the entire IFN administration period, additional antiviral drugs, namely an interferon inducer, are administered to the patient, as well as an amantadine group preparation or a glycyrrhizic acid preparation. At the same time, a concomitant treatment is carried out which involves the administration of T cell immunity stimulators and preparations for combating side effects. The presence of viral ribonucleic acid (RNA) in the patient&#39;s blood is periodically monitored: a daily dose of 800-1200 mg of Ribamidil is administered starting from the third month from the commencement of treatment if ribonucleic acid (RNA) is present in the patient&#39;s blood, or starting from the tenth month if no RNA is present. Treatment is continued until at least a twelve month period of aviremia has passed.
1343154 Radioactive compositions MINNESOTA MINING &amp; MFG CO 19 April 1971 [26 March 1970] 24717/71 Heading G6R For preparing radioactively labelled microparticles for use in medical diagnosis, a container 18 is divided into two compartments by a porous plate 22 and contains microparticles and a labelling reagent; the ends of the container are sealed by stoppers 16, 29 through which a syringe needle may be inserted for introduction of liquid or withdrawal of a suspension of the particles. The microspherical particles may consist of albumin, gelatine, hemoglobin, amylose, insulin, glycogen, colloidal sulphur, or starch, to which ferric hydroxide or silver iodide may be added. When radioteohnetium is being used, a particulate resin hydrogen ion source 24 is provided, held in place by packing 26, and a reagent tablet 20 contains sodium thiosulphate as a reducing agent together with a wetting agent to suspend the microspheres, a filler, binder, and lubricant. A solution containing radiotechnetium is introduced by means of a needle at 29 and passes through the resin 24 and filter plate 22 into compartment 21. The container is agitated, heated, cooled, and the supernatant liquid removed from the labelled microparticles, which are then suspended in saline solution and withdrawn for injection. A layer of granular alumina carrying Mo 99 in the form of ammonium molybdate may be arranged between the resin 24 and the packing 26; radiotechnetium solution is formed when saline solution is introduced through stopper 29 and passes through the alumina into the container 18.
FIELD: cosmetology. SUBSTANCE: the suggested cosmetic mask contains aqueous-alcoholic foundation, biologically active substances, foaming agent. Moreover, as biologically active substances one should apply evening primula&#39;s oil, silk proteins, allatoin, tocopherol acetate, and as foaming agent - PEG-glyceryl cocoate, PEG-glycerides of palm kernel. Moreover, it additionally contains sorbitan laurate, phenoxyethanol or propylparaben, methylparaben gels, or ethylparaben or butylparaben, cetylstearyl alcohol, and water. Components should be taken in certain quantitative content. Method for applying the suggested mask deals with its application onto skin surface. It enables to achieve resistant foaming layer on skin surface. EFFECT: higher efficiency. 2 cl
PROBLEM TO BE SOLVED: To obtain the subject new compound having excellent stability and low side action and useful e.g. as a drug-delivery system of prostaglandin for the prevention, treatment, etc., of various diseases. SOLUTION: This new phospholipidized prostaglandin is expressed by the formula (A is a residue obtained by removing OH from the 1-carboxyl group of a prostaglandin; B is a residue obtained by removing H of 2-hydroxyl group of lysolecithin having hydroxyl group at 2-site of glycerol; (n) is an integer of &gt;=2) (e.g. 6-lysolecithinyl-6-oxohexylamide-prostaglandin E1 ). It is applicable to various prostaglandins and useful e.g. for a drug delivery system capable of achieving the characteristics of a lipid-microsphere agent by chemical bond. The compound can be produced by dissolving prostaglandins in dichloromethane, etc., and reacting with an amino-containing phospholipid in the presence of N,N-dicyclohexylcarbodiimide under cooling.
A devise for trapping cockroaches, composed of a shell, a connector, a big size cockroach trapping component, and a small size cockroach trapping component. The inside of the shell is cockroach path. The outside surface of the shell is coated with the nano-painting material to make it slippery. The connector joins the shell&#39;s female screw and component&#39;s male screw together. The big size cockroach trapping component is hinged with a movable cover to stop the trapped insects from escaping. The small size trapping component is a funnel with many inward pins at the end so as to stop cockroaches from going out. When such a devise is joined with any bottles, the whole set can become an effective and reused cockroach trap.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an effective method for treating a female suffering from female sexual dysfunction (FSD), in particular, female sexual arousal dysfunction (FSAD).  &lt;P&gt;SOLUTION: A method for assaying an agent capable of potentiating cAMP in the sexual genitalia of the female suffering from female sexual dysfunction, in particular, female sexual arousal dysfunction is provided. The agent is an inhibitor of neuropeptide Y (I:NPY). A method and a kit for detecting female sexual dysfunction, in particular, female sexual arousal dysfunction are provided. Non-human animal models, including an anesthetized female animal having a means for measuring change of genitalial blood flow of the animal accompanied with pelvic nerve stimulation, for identifying the agent for treating female sexual dysfunction, in particular, female sexual arousal dysfunction are provided.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
PURPOSE:To provide a safe agent for suppressing formation of lipid peroxide, having low side effect compared with conventional substance and excellent effect for suppressing the formation of lipid peroxide and useful as pharmaceuticals, quasi drugs and cosmetics. CONSTITUTION:The objective effective and safe agent for suppressing the formation of lipid peroxide can be produced by using a lactoferrin as an active component. The amount of the lactoferrin is &gt;=0.001wt.% (preferably &gt;=0.01wt.%) and the agent is coated, rubbed or sprayed (aerosol) to the skin in the form of solution, powder, sol, gel, emulsion, wax and various other forms. It can be used also as an additive for the conventional cosmetic or external agent by conventional process. Since the compound is stable to various other additives and cosmetic bases, it can be used in combination with the substances. Any lactoferrin including those produced by tissue culture or chemical synthesis can be used in the present process provided that the compound has an iron- bonding capability.
PROBLEM TO BE SOLVED: To use an active ingredient comprising a specific compound or its pharmaceutically permissible salt as an incremental agent of recognition, etc., useful for treatment for Alzheimer&#39;s disease or disturbance of memory caused by senility. SOLUTION: Darifenacin, e.g. 3-(s)-(-)-(1-carbamoyl-1,1- diphenylmethyl)-1-[2-(2,3-dihydroxybenzofuran-5-yl)ethyl]pyrrolidine or its pharmaceutically permissible salt is used for a production of a remedy for disturbance of recognition, etc. A daily dose for a human being having 70kg body weight is 3.75-40mg. A combination of the darifenacin or its salt with an inhibitor against acetylcholinesterase (preferably donepizil or its pharmaceutically permissible salt) is especially effective. The medicament is obtained by adding an adjuvant, a diluent or a carrier to the active ingredient.
NEW MATERIAL:The compound of formula I (R is H, 4-6C alkyl, halogen- monosubstituted 3-6C alkyl, etc.; R&#39; is lower alkyl; N is 0-3; when R is H, n is 1-3, and when R is not H, n is 0) and its salt. EXAMPLE:N-n-butyl-N&#39;-geranylgeranylacetylpiperazine. USE:An antiulcer agent having excellent activity against peptic ulcer. It has low toxicity and side effect, and high safety. PREPARATION:The geranylgeranylacetic acid of formula II (X is OH, halogen or lower alkoxy) or its reactive derivative is made to react with the piperazine compound of formula III to obtain the objective compound of formula I . The product is if necessary converted to salt by contacting with an acid.
A pulmonary delivery system includes an elongated body having an openable and closeable portion thereof for receiving an insertable and replaceable container such as a cartridge of pure medical product disposed in a saline solution. The medical product may be epinephrine, insulin or nicotine disposed in a saline solution. The system also incorporates a penetrating element that is disposed in the cylinder to pierce the cartridge and release the nicotine solution into the cylinder and into or on a micron mesh grid. A flow of air created by inhaling through a mouthpiece draws air into an individual&#39;s lungs from an entrainment port and onto a grid for atomizing a mist of micron droplets through the grid. It is recognized that the air from the entrainment port further dilutes the concentration of the medical product. The grid is connected to a source of electrical power to vibrate the mesh grid.
The invention provides improved T cell compositions and methods for manufacturing T cells. More particularly, the invention provides methods of T cell manufacturing that result in adoptive T cell immunotherapies with improved survival, expansion, and persistence in vivo. The invention provides improved T cell compositions and methods for manufacturing T cells. More particularly, the invention provides methods of T cell manufacturing that result in adoptive T cell immunotherapies with improved survival, expansion, and persistence in vivo. A minimally invasive laparoscopic tissue removal device, namely a morcellator. The device includes, from proximal end to distal end, a gripping mechanism, elongate sheath, and mouth, finally terminating in a safety tip. The elongate sheath and mouth are concentric, such that two elongate, rotating cutting/shredding blades/teeth and one elongate auger feed screw can be positioned along the length of the sheath and mouth. The teeth are opposingly disposed and staggered (e.g., 5Â° offset), such that contact with tissue mass grabs and pulls tissue inwards toward the auger, which transports the tissue proximally toward the exterior of the patient&#39;s body (e.g., toward an exit port). A motor unit and gear assembly can be coupled to the teeth and auger to drive rotation of the teeth and auger. A cup assembly can be disposed in overlying relation to the mouth for guiding the tissue mass towards the mouth.
Methods for manufacturing remotely custom fit dental orthotics, where a wearer makes impressions of their upper and lower teeth and also makes a bite impression that determines the relationship of the upper teeth to the lower teeth, preferably in an orthopedically optimized position with respect to each other. The impressions and bite registration are sent by the wearer to a manufacturing facility in a different location. At the manufacturing facility, the impressions are used to make models of the wearer&#39;s upper and lower teeth. The models are mounted on an articulator, and the bite registration is used to position the mounted models in the orthopedically optimized position which is locked in to the articulator. The bite registration is removed and a dental orthotic customized to the wearer and the orthopedically optimized position is formed between the models. The custom orthotic is then sent to the wearer.
PURPOSE:To provide a new compound having an anti-inflammatory effect, an antipyretic and analgesic effect and an antiarthritic effect, reduced in toxicity and useful as an anti-inflammatory drug, especially a therapeutic agent for arthritis. CONSTITUTION:A compound is represented by formula I [Y is N or CG (G is carboxyl); Ring R is a nitrogen-containing unsaturated heterocycle; (n) is 1 to 4; (k) is 0 to 1] or its salt, e.g. 6,7-dimethoxy-4-(3,4-dimethoxyphenyl)-2-(2- ethylimidazol-1-ylmethyl)quinoline-3-carboxylic acid ethyl ester. This compound is synthesized by reacting a compound of formula II (Q is an eliminable group) or its salt with a compound of formula III or its salt in the presence of a base such as sodium hydride in a solvent such as DMF preferably at -10 to 100 deg.C. In addition, the raw material compound of formula II is obtained, e.g. by reacting a 2-aminobenzophenone derivative of formula IV with a compound of the formula QCH2COCH2G&#39; (G&#39; is an esterified carboxyl) in the presence of an acid such as sulfuric acid.
PROBLEM TO BE SOLVED: To produce the subject body capable of efficiently adsorbing an active ingredient by forming the adsorptive body/gradually releasing body having a function adsorbing the active ingredient such as all kinds of chemicals and the function gradually releasing the adsorbed active ingredient from a biopolymer and using a silk protein or an animal-originated keratin, collage, etc., as the biopolymer. SOLUTION: The adsorptive body/gradually releasing body is formed by using the biopolymer having the adsorbing function adsorbing the active ingredient, for example, enzyme, toxin, antibiotic, drug, vaccine, agrochemical, perfume, etc., and the gradually releasing function gradually releasing the adsorbed active ingredient from a biopolymer. The silk protein or the animal-originated keratin, collagen and gelatin are used as the biopolymer. Alternatively, silk fibroin or wool keratin is used as the biopolymer, and the silk fibroin or the wool keratin having &gt;=7% crystallinity based on X-ray diffraction strength analysis is used. A reduced keratin or S-(substd.)alkylkeratin having a SH group can be used.